RPID · Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems delivered first quarter 2026 results showing revenue growth driven by strong product and recurring revenue performance, despite a decline in service revenue due to lower validation activity. Total revenue rose 11.1% to $8.0 million, with product revenue surging 36% to $5.6 million from six new Growth Direct system placements (versus three in Q1 2025), and recurring revenue climbing 27.7% to $5.1 million, representing 63% of total revenue. This underscores robust installed base utilization and consumable pull-through, as highlighted by CEO Robert Spignesi, who noted strong execution and customer interest in enterprise-level QC automation deployments.

Gross profit remained flat at $0.4 million, with margins contracting slightly to 4.6% amid a 12.2% increase in cost of revenue to $7.6 million. Operating expenses rose 17.9% to $14.2 million, driven by 30.8% higher G&A and 24.4% increased sales and marketing, partially offset by 7.3% lower R&D. This led to a wider net loss of $14.3 million or ($0.31) per share, compared to $11.3 million or ($0.26) in the prior year.

Balance sheet liquidity contracted, with cash, equivalents, investments, and restricted cash at $23.2 million as of March 31, 2026, down from $38.6 million at year-end. The company advanced its strategic collaboration with MilliporeSigma via a Services Agreement and reaffirmed full-year 2026 guidance: revenue of $37-41 million including 30-38 system placements, at least 25 validations, and gross margin of ~20% with a mid-20s exit rate in Q4. An updated investor presentation is available on the IR website, with a conference call held on May 13 at 4:30 p.m. ET.